Innoviva (INVA) Cash from Financing Activities (2010 - 2026)
Innoviva posted quarterly Cash from Financing Activities of -$20.1 million for Q1 2026, down 11108.74% year-on-year from N/an in Q1 2025, and down 264.16% on a QoQ basis from $12.3 million in Q3 2025.
Innoviva (INVA) has 17 years of Cash from Financing Activities data on file, last reported at -$20.1 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 11108.74% year-over-year to -$20.1 million; the trailing twelve-month figure through Mar 2026 stood at -$6.4 million (up 77.05% YoY), and the FY2025 full-year result was $8.6 million, up 163.56% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$20.1 million, down from $12.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $60.3 million in Q1 2022 and bottomed at -$157.2 million in Q3 2023.
- The 5-year median for Cash from Financing Activities is -$9.2 million (2023), against an average of -$25.6 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities soared 383.11%; it then slumped 11108.74% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at -$45.6 million in 2022, then slumped by 245.1% to -$157.2 million in 2023, then soared by 91.08% to -$14.0 million in 2024, then surged by 187.49% to $12.3 million in 2025, then sank by 264.16% to -$20.1 million in 2026.
- The last three Cash from Financing Activities figures came in at -$20.1 million (Q1 2026), $12.3 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | -20.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.15 Mn |
| Mar 31, 2026 | -20.15 Mn |
| Sep 30, 2025 | 12.27 Mn |
| Sep 30, 2025 | 12.27 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 183,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Sep 30, 2024 | -14.03 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Mar 31, 2024 | -9.17 Mn |
| Mar 31, 2024 | -9.17 Mn |
| Sep 30, 2023 | -157.25 Mn |
| Sep 30, 2023 | -157.25 Mn |
| Jun 30, 2023 | -9.21 Mn |
| Jun 30, 2023 | -9.21 Mn |
| Mar 31, 2023 | -136.96 Mn |
| Mar 31, 2023 | -136.96 Mn |
| Sep 30, 2022 | -45.57 Mn |
| Sep 30, 2022 | -45.57 Mn |
| Jun 30, 2022 | -9.74 Mn |
| Jun 30, 2022 | -9.74 Mn |
| Mar 31, 2022 | 60.33 Mn |
| Mar 31, 2022 | 60.33 Mn |
| Sep 30, 2021 | -440.43 Mn |
| Sep 30, 2021 | -440.43 Mn |
| Jun 30, 2021 | -414.26 Mn |
| Jun 30, 2021 | -414.26 Mn |
| Mar 31, 2021 | -21.31 Mn |
| Mar 31, 2021 | -21.31 Mn |
| Dec 31, 2020 | -2.51 Mn |
| Dec 31, 2020 | -2.51 Mn |
| Sep 30, 2020 | -12,000.00 |
| Sep 30, 2020 | -12,000.00 |
| Jun 30, 2020 | -11.63 Mn |
| Jun 30, 2020 | -11.63 Mn |
| Mar 31, 2020 | -15.64 Mn |
| Mar 31, 2020 | -15.64 Mn |
| Dec 31, 2019 | -13.75 Mn |
| Dec 31, 2019 | -13.75 Mn |
| Sep 30, 2019 | -10.47 Mn |
| Sep 30, 2019 | -10.47 Mn |
| Jun 30, 2019 | 198,000.00 |
| Jun 30, 2019 | 198,000.00 |
| Mar 31, 2019 | 246,000.00 |
| Mar 31, 2019 | 246,000.00 |
| Dec 31, 2018 | -2.38 Mn |
| Dec 31, 2018 | -2.38 Mn |
| Sep 30, 2018 | -112.25 Mn |
| Sep 30, 2018 | -112.25 Mn |
| Jun 30, 2018 | -715,000.00 |
| Jun 30, 2018 | -715,000.00 |
| Mar 31, 2018 | -122.63 Mn |
| Mar 31, 2018 | -122.63 Mn |
| Dec 31, 2017 | -87.06 Mn |
| Dec 31, 2017 | -87.06 Mn |
| Sep 30, 2017 | -10.93 Mn |
| Sep 30, 2017 | -10.93 Mn |
| Jun 30, 2017 | -56.84 Mn |
| Jun 30, 2017 | -56.84 Mn |
| Mar 31, 2017 | -8.36 Mn |
| Mar 31, 2017 | -8.36 Mn |
| Dec 31, 2016 | -19.58 Mn |
| Dec 31, 2016 | -19.58 Mn |
| Sep 30, 2016 | -24.84 Mn |
| Sep 30, 2016 | -24.84 Mn |
| Jun 30, 2016 | -26.80 Mn |
| Jun 30, 2016 | -26.80 Mn |
| Mar 31, 2016 | -26.35 Mn |
| Mar 31, 2016 | -26.35 Mn |
| Dec 31, 2015 | -25.77 Mn |
| Dec 31, 2015 | -25.77 Mn |
| Sep 30, 2015 | -25.61 Mn |
| Sep 30, 2015 | -25.61 Mn |
| Jun 30, 2015 | -27.83 Mn |
| Jun 30, 2015 | -27.83 Mn |
| Mar 31, 2015 | -27.71 Mn |
| Mar 31, 2015 | -27.71 Mn |
| Dec 31, 2014 | -9.75 Mn |
| Dec 31, 2014 | -9.75 Mn |
| Sep 30, 2014 | -7.86 Mn |
| Sep 30, 2014 | -7.86 Mn |
| Jun 30, 2014 | 148.42 Mn |
| Jun 30, 2014 | 148.42 Mn |
| Mar 31, 2014 | 18.27 Mn |
| Mar 31, 2014 | 18.27 Mn |
| Dec 31, 2013 | 13.02 Mn |
| Dec 31, 2013 | 13.02 Mn |
| Sep 30, 2013 | 113.57 Mn |
| Sep 30, 2013 | 113.57 Mn |
| Jun 30, 2013 | 23.39 Mn |
| Jun 30, 2013 | 23.39 Mn |
| Mar 31, 2013 | 247.86 Mn |
| Mar 31, 2013 | 247.86 Mn |
| Dec 31, 2012 | 6.72 Mn |
| Dec 31, 2012 | 6.72 Mn |
| Sep 30, 2012 | 12.42 Mn |
| Sep 30, 2012 | 12.42 Mn |
| Jun 30, 2012 | 214.26 Mn |
| Jun 30, 2012 | 214.26 Mn |
| Mar 31, 2012 | 2.48 Mn |
| Mar 31, 2012 | 2.48 Mn |
| Dec 31, 2011 | 2.85 Mn |
| Dec 31, 2011 | 2.85 Mn |
| Sep 30, 2011 | 1.31 Mn |
| Sep 30, 2011 | 1.31 Mn |
| Jun 30, 2011 | 9.77 Mn |
| Jun 30, 2011 | 9.77 Mn |
| Mar 31, 2011 | 11.67 Mn |
| Mar 31, 2011 | 11.67 Mn |
| Dec 31, 2010 | 133.34 Mn |
| Dec 31, 2010 | 133.34 Mn |
| Sep 30, 2010 | 1.38 Mn |
| Sep 30, 2010 | 1.38 Mn |